

**Table e-2. Long-term seizure outcome related to histopathology**

|                 | n  | Sustained seizure freedom<br>n (%) | Seizure free last year of follow-up<br>n (%) | Seizures<br>n (%) |
|-----------------|----|------------------------------------|--|-------------------|
| <b>HS</b>       | 45 | 21 (47)                            | 6 (13)                                       | 18 (40)           |
| <b>DNET+GGL</b> | 34 | 20 (59)                            | 6 (18)                                       | 8 (24)            |
| <b>AST</b>      | 21 | 9 (43)                             | 3 (14)                                       | 9 (43)            |
| <b>CAH</b>      | 21 | 14 (67)                            | 3 (14)                                       | 4 (19)            |
| <b>MCD</b>      | 52 | 17 (33)                            | 6 (12)                                       | 29 (56)           |
| <b>Gliosis</b>  | 65 | 21 (32)                            | 12 (18)                                      | 32 (49)           |
| <b>Other</b>    | 40 | 15 (38)                            | 8 (20)                                       | 17 (43)           |

Abbreviations: HS = hippocampal sclerosis, DNET+GGL = neurodevelopmental tumors (dysembryoplastic neuroepithelial tumors and gangliogliomas), AST = low-grade astrocytomas, CAH = cavernous hemangiomas, MCD = malformations of cortical development. Other includes vascular malformations other than CAH, cysts, tuberous sclerosis and unknown histopathology.